Aptus Capital Advisors LLC Has $835,000 Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Aptus Capital Advisors LLC boosted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 5.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,969 shares of the medical equipment provider’s stock after purchasing an additional 520 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Boston Scientific were worth $835,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Koshinski Asset Management Inc. bought a new position in Boston Scientific in the 1st quarter valued at about $250,000. HBK Sorce Advisory LLC acquired a new stake in Boston Scientific during the 1st quarter worth approximately $714,000. Kingsview Wealth Management LLC boosted its stake in Boston Scientific by 4.1% in the 1st quarter. Kingsview Wealth Management LLC now owns 5,570 shares of the medical equipment provider’s stock valued at $381,000 after purchasing an additional 219 shares during the period. Blair William & Co. IL grew its holdings in Boston Scientific by 9.3% in the 1st quarter. Blair William & Co. IL now owns 18,312 shares of the medical equipment provider’s stock valued at $1,254,000 after buying an additional 1,560 shares in the last quarter. Finally, Dorsey & Whitney Trust CO LLC increased its position in Boston Scientific by 15.3% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 13,016 shares of the medical equipment provider’s stock worth $891,000 after buying an additional 1,732 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the transaction, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The trade was a 15.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the sale, the executive vice president now directly owns 160,467 shares of the company’s stock, valued at approximately $13,639,695. The trade was a 45.23 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 309,270 shares of company stock worth $26,196,718. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $87.59 on Friday. The business has a 50-day simple moving average of $85.03 and a two-hundred day simple moving average of $79.33. Boston Scientific Co. has a 12-month low of $53.56 and a 12-month high of $89.30. The stock has a market cap of $129.09 billion, a PE ratio of 72.39, a PEG ratio of 2.61 and a beta of 0.79. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the prior year, the firm posted $0.50 earnings per share. The firm’s revenue was up 19.3% compared to the same quarter last year. Analysts anticipate that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of a number of recent research reports. StockNews.com cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. TD Cowen raised their target price on shares of Boston Scientific from $86.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Robert W. Baird boosted their price target on Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Wells Fargo & Company increased their price target on Boston Scientific from $87.00 to $98.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. Finally, Royal Bank of Canada lifted their price objective on Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $93.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.